The Endeavour contract gives Bain a hat-trick in getting work at the companies its former partner Hrdlicka heads up.

Endeavour has been under considerable pressure to turn around its share price decline, and earlier this week told investors ...

Anne Hoecker, Bain & Company's head of global technology practice, joins CNBC's 'Squawk on the Street' to discuss the growth ...

The new company will work on five experimental drugs licensed from Bristol Myers, including a late-stage lupus treatment and ...

A newly-acquired Bain Capital company in Japan that makes airplane seats, toilets and galleys is betting its US-based ...

The most successful carve-out acquisitions start with due diligence that identifies both the carve-out-specific elements and ...

Bain is closing its business in Johannesburg, likely bringing to an end a yearslong battle to try and restore its reputation.

Delivering accelerated business transformations by leveraging the most advanced technology platforms and solutions ...

Pharma is looking for fewer, scaled providers at an enterprise level to reduce risk and provide a better-integrated service,' ...

The newly formed biotech launches with five promising autoimmune candidates, $300 million in funding, and leadership from ...

Bain & Co has decided to shut its consultancy business in South Africa, where it has struggled to shake off the “stigma” of ...

Bain Capital and Bristol Myers Squibb have formed a new biopharmaceutical company focused on developing new therapies for autoimmune diseases. The newly formed company launches with a $300 million ...